Studies on the crystal forms of pefloxacin: Preparation, characterization, and dissolution profile

Journal of Pharmaceutical Sciences

Volumn 97, Issue 7, 2008, Pages 2637-2648

  Yadav, Mange Ram ^a   Shaikh, Anwar R ^a   Ganesan, V ^a   Giridhar, Rajani ^a   Chadha, Renu ^b  

^a M S UNIVERSITY OF BARODA   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Calorimetry (DSC); Dissolution rate; FTIR; Polymorphism; Preformulation; Thermal analysis; X ray powder diffractometry

Indexed keywords

PEFLOXACIN;

ABSORPTION SPECTROSCOPY; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STRUCTURE; GAS CHROMATOGRAPHY; THERMOGRAVIMETRY; X RAY DIFFRACTION;

EID: 52449119963     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21178     Document Type: Article

References (16)

1. Grant DJW. 1994. Polymorphism in pharmaceutical solids. New York: Marcel Dekker. pp. 1-83.
2. Halebilian J, McCrone W. 1969. Pharmaceutical applications of polymorphism. J Pharm Sci 58:911-929.
3. Guillary J. 1999. Polymorphism in pharmaceutical solids. New York: Marcel Dekker. pp. 183-226.
4. Sweetman SC. 2005. Martindale, the complete drug reference. 34th edition. London: Pharmaceutical Press, pp. 119-120.
5. Neumann P, Dopp C. 1989. Fluoroquinolones-anti-bacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs. Internist (Berl) 30:20-31.
6. Korzets Z, Pomeranz A, Golan E, Bernheim J. 1997. Pefloxacin in adriamycin induced nephrotic syndrome in the rat. Nephrol Dial Transplant 12: 286-288.
7. Petra D, Janez K, Gerald G, Iztock T. 2006. X-ray crystallographic, NMR and antimicrobial activity of magnesium complex of fluoroquinolones-racemic ofloxacin and its S-form Levofloxacin. J Inorg Biochem 100:1755-1763.
8. Barbes R, Marti F, Prohens R. 2006. Polymorphism of Norfloxacin: Evidence of the enatiotropic relationship between polymorphs A and B. Cryst Grow Desgn 6:1463-1467.
9. Wallis SC, Gahan LR, Charles BG, Hambley TW, Duckworth PAJ. 1996. Copper (II) complex of fluoroquinolones antimicrobial ciprofloxacin, synthesis, X-ray structural characterization and potentiometer study. Inorg Biochem 62:1-61.
10. Leban I, Turel I, Bukovec N. 1997. Crystal structure and characterization of the bismuth (III) compound with quinoline family member (ciprofloxacin): Antibacterial study. J Inorg Biochem 66:241-245.
11. Sadeek A, Maomen R, Hassan A. 2006. Complexation and thermogravimetric investigation on Tin (II) and Tin (IV) with norfloxacin agent. J Cord Chem 59:759-775.
12. +3. J Pharm Sci 51:1009-1021.
13. Jorgensen ED, Bhagwat D. 1998. Development of dissolution tests for oral extended release products. Pharm Technol Today 1:128-135.
14. Hart A, Barber HE, Calvey TN. 1975. Bioavailability and dissolution of different formulations of oxytetracyline preparations. Br J Clin Pharmacol 2: 277-280.
15. Hoepelman IM, Visser MR, Rozenberg MMA, Beumer H, Verhoef J. 1991. Comparative in vitro antibacterial activity of sparfloxacin, a new quinolone. Antimicrob Agent Chemothe 35:858-868.
16. Thangadurai S, Shukla S, Srinivasan AK, Anjan-eyulu Y. 2003. X-ray powder diffraction patterns for certain fluoroquinolone antibiotic drugs. Acta Pharm 53:295-303.